Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Dyslipidemia and atypical antipsychotic drugs.

Casey DE.

J Clin Psychiatry. 2004;65 Suppl 18:27-35. Review.

2.

Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.

Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA.

J Clin Psychopharmacol. 2008 Apr;28(2):132-7. doi: 10.1097/JCP.0b013e318166c4f7.

PMID:
18344722
3.

Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study.

Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, Lindeman S.

J Clin Psychiatry. 2004 Apr;65(4):547-50.

PMID:
15119919
4.

Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan.

Huang TL, Chen JF.

Schizophr Res. 2005 Dec 1;80(1):55-9. Epub 2005 Jun 17.

PMID:
15964176
5.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

6.

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

Meyer JM, Koro CE.

Schizophr Res. 2004 Sep 1;70(1):1-17. Review.

PMID:
15246458
7.

[Metabolic risk during antipsychotic treatment in patients with schizophrenia].

Rzewuska M.

Psychiatr Pol. 2007 Jul-Aug;41(4):457-72. Review. Polish.

PMID:
18046977
8.

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

J Clin Psychiatry. 2003 May;64(5):598-604.

PMID:
12755665
9.

Hyperglycemia and antipsychotic medications.

Haupt DW, Newcomer JW.

J Clin Psychiatry. 2001;62 Suppl 27:15-26; discussion 40-1. Review.

10.

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

Stahl SM, Mignon L, Meyer JM.

Acta Psychiatr Scand. 2009 Mar;119(3):171-9. doi: 10.1111/j.1600-0447.2008.01334.x. Review.

PMID:
19178394
11.

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC.

Arch Gen Psychiatry. 2005 Jan;62(1):19-28.

PMID:
15630069
12.

The effects of novel antipsychotics on glucose and lipid levels.

Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC.

J Clin Psychiatry. 2002 Oct;63(10):856-65.

PMID:
12416594
13.

Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.

Brown RR, Estoup MW.

Int Clin Psychopharmacol. 2005 Mar;20(2):105-12.

PMID:
15729087
14.

Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.

Newcomer JW.

J Clin Psychiatry. 2004;65 Suppl 18:36-46. Review.

15.

Atypical antipsychotic therapy and hyperlipidemia: a review.

Koro CE, Meyer JM.

Essent Psychopharmacol. 2005;6(3):148-57. Review.

PMID:
15869022
16.

Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.

Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B.

Pharmacogenomics J. 2008 Jun;8(3):228-36. Epub 2007 Aug 28.

PMID:
17726453
17.

Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.

Garyfallos G, Dimelis D, Kouniakis P, Sidiropoulos N, Karastergiou A, Lavrentiadis G, Giouzepas J, Fokas K.

Eur Psychiatry. 2003 Oct;18(6):320-1. No abstract available.

PMID:
14611929
18.

Clozapine-induced severe mixed hyperlipidemia: a case report.

Ahmed M, Griffin D, O'Toole R, McDonald C.

Gen Hosp Psychiatry. 2009 Jan-Feb;31(1):93-6. doi: 10.1016/j.genhosppsych.2008.07.003. Epub 2008 Sep 5.

PMID:
19134516
19.

Should lipids be monitored during the first year of treatment with an atypical antipsychotic?

Landry P, Benaliouad F.

Can J Psychiatry. 2003 Jun;48(5):348-9. No abstract available.

PMID:
12866344
20.

Metabolic risk during antipsychotic treatment.

Newcomer JW.

Clin Ther. 2004 Dec;26(12):1936-46. Review.

PMID:
15823759

Supplemental Content

Support Center